Clinical Trials Logo

Clinical Trial Summary

Catheter related infections (CRIs) were found to be associated with several risk factors, including patient related risk factors such as age, gender, clinical status and catheter related risk factors such as the vascular access location, dwelling time, catheter type and number of lumens. In addition to the inserted solution type and the experience of the professional who performs the procedure ,These factors constitute important strategic points for actions to compare the infectious complications of peripheral versus central venous catheters in critically ill patients.


Clinical Trial Description

Nosocomial (hospital-acquired) bloodstream infections (BSIs) are an important cause of morbidity and mortality, with an estimated 250,000 cases occurring each year in the United States.

BSIs may be either primary or secondary. Secondary infections are related to infections at other sites, such as the urinary tract, lung, postoperative wounds, and skin. Most nosocomial BSIs are primary, as illustrated by the United States Centers for Disease Control and Prevention's National Nosocomial Infection Surveillance system, in which 64 percent of the nosocomial BSIs reported were primary BSIs. While some primary BSIs have no identifiable source, most are associated with intravascular catheters, and central venous catheters (CVCs) in particular.

Critically ill patients require intravenous administration of fluids and drugs.This can be achieved via peripheral or central catheters. Each device is associated with both mechanical and infectious complications. Complications associated with central lines are judged to be more severe. Some patients actually require the insertion of a central line due to the venous toxicity of the drugs or to the necessity of making sure that the infusion is regularly administered (example: high dose catecholamine infusion). Some physicians believe that most Intensive Care Unit (ICU) patients should have a central venous line inserted, whereas others feel that some patients may receive active drugs via a peripheral line in selected instances.

Endpoints are the rate of mechanical complications (difficulty in inserting the line, need for repeat insertion attempts, occurrence of arterial puncture, occurrence of pneumothorax) and of infectious complications (local catheter infection or catheter-related bloodstream infection). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03379948
Study type Observational [Patient Registry]
Source Assiut University
Contact mohamed maghraby, MD
Phone 01010685968
Email maghraby@gmail.com
Status Not yet recruiting
Phase N/A
Start date February 1, 2018
Completion date February 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT01597973 - Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME) Phase 3
Active, not recruiting NCT02743585 - Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT) N/A
Completed NCT01396642 - Topical Emollient Therapy N/A
Completed NCT02682355 - Optimizing Clinical Use of Polymyxin B
Completed NCT03284398 - Three-Chamber Bags Retrospective Study in Spain
Recruiting NCT05016752 - Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream Infection